DJ Sutro Biopharma Doses First Patient on Ovarian Cancer Treatment Study
By Chris Wack
Sutro Biopharma Inc. said Thursday it has dosed the first patient in the dose-expansion cohort of its Phase 1 STRO-002 study.
STRO-002 is a folate receptor alpha targeting antibody-drug conjugate for the potential treatment of ovarian cancer.
The company said the dose-expansion cohort will assess the efficacy, safety and tolerability of STRO-002 at 4.3 and 5.2 mg/kg, given every three weeks in patients with ovarian cancer. The dose-expansion cohort for folate receptor alpha-selected endometrial cancer is planned for later this year.
Sutro said it plans to expand the study to 35 clinical sites in the U.S. and Europe. The dose-expansion study includes two patient cohorts, advanced epithelial ovarian cancer and endometrial cancer.
Sutro Biopharma shares were up 17% to $30.86 in premarket trading.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
January 21, 2021 08:16 ET (13:16 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.